SLU-PP-915 VS SLU-PP-332: What are the differences between these pan-err agonists?
Leave a message
What Are SLU-PP-915 and SLU-PP-332?
Both SLU-PP-915 and SLU-PP-332 are synthetic small molecules and Pan-ERR agonists intended solely for laboratory research. Although they are not the same compound, they have similar effects.
| Name: | SLU-PP-915 | SLU-PP-332 |
| IUPAC Name: | [3-[5-[(2-fluorophenyl)carbamoyl]thiophen-2-yl]phenyl]boronic acid | 4-hydroxy-N-[(E)-naphthalen-2-ylmethylideneamino]benzamide |
| CAS NO. | 2285432-92-8 | 303760-60-3 |
| MF: | C17H13BFNO3S | C18H14N2O2 |
| MW: | 341.16 | 290.32 |
| EINECS: | 225-599-8 | 218-362-5 |
| InChI: | InChI=1S/C17H13BFNO3S/c19-13-6-1-2-7-14(13)20-17(21)16-9-8-15(24-16)11-4-3-5-12(10-11)18(22)23/h1-10,22-23H,(H,20,21) | InChI=1S/C18H14N2O2/c21-17-9-7-15(8-10-17)18(22)20-19-12-13-5-6-14-3-1-2-4-16(14)11-13/h1-12,21H,(H,20,22)/b19-12+ |
| Oral Bioavailability: | Limited | Improved |
| Structure: |  |
 |
| Receptor target: | Pan-ERR agonist (ERRα / ERRβ / ERRγ) | |
| Regulatory Status: | Not approved by the FDA for human use | |
Mechanism of Action
Common Mechanisms of Action
1. SLU-99-332 and SLU-PP-915 are potential ERR agonists that have been shown to target all three isoforms of the ERR (ERRα, ERRβ, and ERRγ).
2. Both improve energy metabolism by mimicking aerobic exercise.
3. SLU-99-332 and SLU-PP-915 can induce DNA damage-induced transcript 4 (Ddit4)
4. They support mitochondrial health.
Key Differences
Although the SLU-99-332 compound has been shown in mouse studies to enhance aerobic exercise capacity, SLU PP 332 has low oral bioavailability. In contrast, the SLU-PP-915 compound not only exhibits strong in vivo exercise-mimicking activity but also has high oral bioavailability.
Why Was SLU-PP-915 Developed?
SLU-PP-915 can be considered an upgraded version of SLU-99-332. Why was this new compound developed? Researchers sought to retain the ERR pan-agonist activity and the research value of the exercise mimetic while redesigning the molecular scaffold. By adopting a unique scaffold structure, the compound demonstrated superior pharmacokinetic properties in laboratory testing. Key optimizations were made to address the poor oral bioavailability of SLU-99-332. SLU-PP-915 is also more stable than SLU-PP-332.
Which Compound May Be More Suitable for Research?
Neither SLU-PP-915 nor SLU-99-332 is currently used in humans; they are primarily used for scientific research. Research suggests they may have the potential to improve energy production, enhance mitochondrial efficiency, and support cellular health; they may also be involved in mitochondrial cell functions and have anti-aging potential. Additionally, they may be related to the protection of brain cells and are being studied in the context of neuroprotection. Furthermore, they may support fat metabolism and are being investigated in chemical research as components related.
Why Source SLU-PP-915 and SLU-PP-332 from Jinan Jianfeng Chemical?
For scientific research and corporate procurement, suppliers that have undergone HPLC testing and can provide relevant product documentation, such as a Certificate of Analysis (COA), are the best choice. Jinan Jianfeng Chemical Co., Ltd. provides high-purity SLU-PP-915 powder and SLU-99-332 powder to global buyers. Our advantages are as follows:
1. We operate our own R&D and analytical laboratories as well as manufacturing facilities, ensuring consistent quality and batch-to-batch uniformity for all products.
2. With no geographical restrictions, SLU-PP-332 and SLU-PP-915 can be shipped worldwide, and we have customs clearance agents in various regions.
3. With 15 years of export experience, we maintain comprehensive technical documentation and provide a stable supply.
4. We support product customization, OEM packaging services, and the development of various dosage forms.
FAQ
1. Is SLU-PP-915 a peptide?
SLU-PP-915 is a synthetic small-molecule compound in powder form; it is not a peptide. Its CAS number is 2285432-92-8, and its molecular weight is 341.16 g/mol.
2. Are both compounds pan-ERR agonists?
SLU-PP-915 and SLU-PP-332 are both pan-ERR agonists-synthetic research compounds primarily used to regulate gene expression and mimic aerobic exercise.
3. Have the compounds SLU-PP-915 and SLU-PP-332 been approved for use in humans?
SLU-PP-915 and SLU-PP-332 have not received approval for use in humans or from regulatory authorities; they are currently in the animal testing and laboratory research phases, and their safety in humans cannot be assessed.
4. What is the main difference between SLU-PP-915 and SLU-PP-332?
As a new-generation Pan-ERR agonist, SLU-PP-915 addresses the issue of low oral bioavailability in SLU-PP-332 without altering its primary mechanism of action; this is the main difference between the two.
5. Can laboratories purchase both compounds?
Jinan Jianfeng Chemical Co., Ltd. provides high-quality SLU-PP-915 and SLU-PP-332 powder to laboratories, R&D personnel, and various B2B buyers.
6. Are these compounds intended for research?
Yes.
7. Do you provide COA and analytical documents?
Yes, Jinan Jianfeng Chemical Co., Ltd. provides product documentation such as COA and MSDS to procurement personnel.
Disclaimer:
The information on this website is for communication and learning purposes only and is not medical advice. It should not be used for diagnosing or treating any illness.
References
Billon C, Appourchaux K, Côté I, Burris TP. An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. Journal of Pharmacology and Experimental Therapeutics. 2025;393(1):103787. doi:10.1016/j.jpet.2025.103787.
Möller T, Krug O, Thevis M. In Vitro Metabolism and Analytical Characterization of SLU‐PP‐332 and SLU‐PP‐915: Novel Pan‐ERR Agonists With Doping Potential. Rapid Communications in Mass Spectrometry. 2026;40(8):e70039. doi:10.1002/rcm.70039. (pmc.ncbi.nlm.nih.gov)
Hampton CS, Sitaula S, Billon C, Haynes K, Avdagic A, Wanninayake U, Adeyemi CM, Chatterjee A, Griffett K, Banerjee S, Burris SL, Schoepke E, Boehm T, Bess A, de Vera IMS, Burris TP, Walker JK. Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915. European Journal of Medicinal Chemistry. 2023;258:115582. doi:10.1016/j.ejmech.2023.115582
Billon C, Appourchaux K, Côté I, Burris TP, et al. An orally active estrogen receptor–related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. Journal of Pharmacology and Experimental Therapeutics. 2025. PMID: 41421047
Xu W, Billon C, Li H, Wilderman A, Qi L, Graves A, Dela Cruz Rideb JR, Zhao Y, Hayes M, Yu K, Losby M, Hampton CS, Adeyemi CM, Hong SJ, Nasiotis E, Fu C, Oh TG, Fan W, Downes M, Welch RD, Evans RM, Milosavljevic A, Walker JK, Jensen BC, Pei L, Burris T, Zhang L. Novel pan-ERR agonists ameliorate heart failure through enhancing cardiac fatty acid metabolism and mitochondrial function. Circulation. 2024;149(3):227–250. doi:10.1161/CIRCULATIONAHA.123.066542
Losby M, Hayes M, Valfort A, Sopariwala DH, Sanders R, Walker JK, Xu W, Narkar VA, Zhang L, Billon C, Burris TP. The estrogen receptor-related orphan receptors regulate autophagy through TFEB. Molecular Pharmacology. 2024;106(4):164–172. doi:10.1124/molpharm.124.000889
